Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178607 | 0.78 | LTA4H (0.45) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL2470101 | 0.78 | LTA4H (0.45) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL3087192 | 0.78 | LTA4H (0.45) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL9660788 | 0.77 | TDP1 (0.48) | TDP1ATML3MBTL1ALOX15HPGD | |
| Bicarbonate SCHEMBL27833263 | 0.76 | TDP1 (0.52) | TDP1ATML3MBTL1ALOX15HPGD | |
| Bicarbonate SCHEMBL21879667 | 0.76 | TDP1 (0.52) | TDP1ATML3MBTL1ALOX15HPGD | |
| Bicarbonate SCHEMBL1393750 | 0.76 | TDP1 (0.52) | TDP1ATML3MBTL1ALOX15HPGD | |
| Bicarbonate SCHEMBL9240263 | 0.76 | TDP1 (0.52) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL11171421 | 0.76 | LTA4H (0.43) | TDP1ATML3MBTL1ALOX15HPGD | |
| SCHEMBL55636 | 0.76 | TDP1 (0.52) | TDP1ATML3MBTL1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| US-5670489-A | USEFUL IN TREATMENT OF DISEASES WHICH ARE MODULATED BY PROTEINS, OR IN TREATMENT OF VIRUSES SUCH AS INFLUENZA, HERPES, AND HIV | NOVARTIS CORPORATION (US) | 1997-09-23 | — | — | US | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |
| WO-1996007666-A1 | MONONUCLEOTIDE AND DINUCLEOTIDE ANALOGUES AND INTERMEDIATES THEREFOR | NOVARTIS AG (CH) | 1996-03-14 | — | — | WO | claimed |
| US-5466677-A | Dinucleoside phosphinates and their pharmaceutical compositions | CIBA-GEIGY CORPORATION (US) | 1995-11-14 | — | — | US | claimed |
| EP-0629633-A2 | Dinucleotide analogues, intermediates therefor and oligonucleotides derived therefrom | CIBA-GEIGY AG (CH) | 1994-12-21 | — | — | EP | claimed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | claimed |
| EP-0614907-A1 | Dinucleotide and oligonucleotide analogues | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | claimed |
| JP-10298186-A | — | — | None | — | — | JP | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| US-6930104-B2 | Heterocyclic derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-16 | — | — | US | disclosed |
| US-20040157850-A1 | Novel heterocyclic derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993006112-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0120374-B1 | 2-DESOXYOXANOSINE, A PROCESS FOR THE PREPARATION THEREOF AND ITS USE AS A MEDICAMENT | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4530998-A | 2'-Deoxyoxanosine | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1985-07-23 | — | — | US | disclosed |
| EP-0120374-A1 | 2-Desoxyoxanosine, a process for the preparation thereof and its use as a medicament | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157850-A1 | Novel heterocyclic derivatives | APP, BACE1, PSEN1 | TDP1 843/4885ATM 1822/4885L3MBTL1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.